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Fibronectin accumulation in glomerulosclerotic lesions: Self- Accumulation of extracellular matrix (ECM) mole-
assembly sites and the heparin II binding domain. cules in the glomerulus leads to the development of glo-
Background. Glomerulosclerosis is a severe complication of merulosclerosis, which is a prominent feature of manymany immunologically-mediated kidney diseases, eventually
immunologically-mediated renal diseases. Glomerulo-resulting in loss of renal function. In chronic graft-versus-host
sclerosis, together with tubulointerstitial fibrosis, causesdisease (GvHD) in mice, a model for human lupus nephritis,
the end-stage sclerotic lesions were previously shown to contain irreversible end-stage renal damage with poor patient
large amounts of fibronectin (FN). This study investigated a prognosis. Vleming et al reported that of a number of
domain-specific accumulation process of circulating plasma FN matrix molecules in a variety of human renal diseases,(pFN) in sclerotic lesions.
only the amount of intraglomerular fibronectin (FN) de-Methods. GvHD mice were injected with FITC-conjugated
position correlates with the severity of glomerular struc-pFN or pFN-fragments, with or without heparin pre-incuba-
tion. pFN fragments were generated by digestion of pFN by tural abnormalities, and inversely with renal function [1].
cathepsin D, after which the fragments were separated on a Fibronectin is a large adhesive glycoprotein that is
heparin affinity column. Thus, two batches of fragments were widely distributed as cellular FN (cFN) in the ECM ofobtained with either low or high affinity for heparin.
various tissues and on cell surfaces, and as soluble plasmaResults. FN accumulation was accompanied by an up-regu-
FN (pFN) in the circulation. FN is involved in the regu-lated expression of integrin 51, the FN receptor, in the periph-
ery of sclerotic lesions. pFN-FITC injected into GvHD mice lation of cell adhesion, differentiation, migration, and
was trapped in sclerotic glomeruli within 24 hours. Both hepa- proliferation. This multifunctional protein consists of a
rin and non-anti-coagulant heparin blocked the accumulation dimer of two disulfide-bonded subunits, each with a mo-of pFN-FITC, indicating that the protective effect of heparin
lecular weight of approximately 220 kD, that containin the trapping of FN is independent of its anticoagulant prop-
erties, and probably results from preventing direct binding of binding sites for heparin, collagen, DNA, integrins, and
FN in the sclerotic lesions. To investigate whether FN binds in FN itself [2, 3]. In the normal kidney FN is located in
the glomerulus via the heparin-binding regions, pFN fragments the mesangium, the glomerular basement membrane
were generated and injected into GvHD mice. Whereas the
(GBM), Bowman’s capsule and the tubular basementfraction with high affinity for heparin did not accumulate in
membrane (TBM) [4]. FN has a crucial role in the organi-the sclerotic glomeruli, the fraction with low affinity for heparin
did. Partial sequencing of the isolated peptides showed that in zation of ECM components, and is considered to play a
the glomerulus fibronectin does not bind via the heparin II key part in the pathogenesis of some glomerulonephri-
binding region. tides, where the molecule is present in increased amounts
Conclusions. We hypothesize that the protective effect of
in the expanded mesangium [5, 6].heparin treatment may be the result of steric hindrance of the
Chronic graft-versus-host disease (GvHD) in mice isspecific binding sites, that is, the I1-5 and/or III1 self-assembly
sites of FN. an experimental model for human systemic lupus erythe-
matosus (SLE), in which a transfer of donor lymphocytes
into F1-hybrid recipients causes uncontrolled B-cell acti-
vation with production of autoantibodies [7]. This results
in an immune complex glomerulonephritis, resembling
human lupus nephritis [8]. Both in the GvHD model andKey words: fibronectin, glomerulosclerosis, chronic graft-versus-host
disease, extracellular matrix, renoprotection. in human renal diseases, the end-stage glomerulosclero-
tic lesions consist mainly of FN, which accumulates as aReceived for publication May 17, 2001
result of specific trapping of pFN from the circulationand in revised form September 17, 2001
Accepted for publication September 18, 2001 rather than through de novo synthesis [9]. The mecha-
nism by which the specific accumulation of pFN in the 2002 by the International Society of Nephrology
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sclerotic lesions takes place is still unknown. FN accumu- recipients on days 0, 3, 7, and 10. Each dose of 25*106
viable DBA/2 cells in 0.25 mL HBSS was composed oflation may result from its involvement in the blood coag-
ulation system, or via direct binding of pFN to cells or approximately 60% spleen cells, 30% thymocytes, and
10% lymph-node cells.other ECM components in the damaged glomerulus.
Because the accumulation of FN in the end-stage
Accumulation experimentsglomerulosclerotic lesions may be the result of an activa-
tion of the coagulation cascade, we studied the effect of All accumulation experiments were performed 10 to
12 weeks after the induction of GvHD, since specificheparin on the glomerular accumulation of FITC-labeled
pFN in the GvHD model. Heparin is a sulfated glycos- trapping of pFN in the glomerulosclerotic lesions has
been shown to occur at this time point. GvHD mice wereaminoglycan, closely related to heparan sulfate, with a
long history in the treatment of patients with thrombotic injected intravenously with 500 g FITC-conjugated
mouse pFN with or without 250 U (non-anticoagulant)diseases. Many ECM components, such as fibronectin,
laminin, thrombospondin and different types of collagen, heparin. This is approximately 15% of the normal total
plasma FN content of a mouse as estimated by a quantita-can bind to heparin. In addition to its anti-coagulant
function, heparin has an impact on interactions that in- tive sandwich-ELISA technique (unpublished results).
Where appropriate, pFN and either heparin or non-anti-volve matrix organization, cell adhesion, proliferation,
and cytokine action [reviewed in 10]. With regard to the coagulant heparin were incubated together for one hour
at 37C before injection, after which the solution waskidney, heparin was shown to have an antiproliferative
effect on cultured vascular smooth muscle cells, epithe- spun down for 30 seconds to remove FITC-crystals. pFN-
heparin complexes remained soluble during the incuba-lial cells, and mesangial cells [11–14]. In several models,
such as renal ablation, MRL/lpr mice, puromycin amino- tion and centrifugation step.
Plasma fibronectin fragments were obtained as de-nucleoside-induced nephrotic syndrome, and anti-Thy
1.1 nephritis in the rat, administration of heparin dimin- tailed below. Accumulation experiments with the pFN
fragments were performed with 250 g of the FITC-ished proteinuria and hypertension, and decelerated the
progression of renal insufficiency and glomerulosclerosis conjugated low-affinity pFN fraction or 125 g of the
FITC-conjugated high-affinity pFN fraction, with orin vivo [15–19].
Our results show that both heparin and N-desulfated without 250 U heparin. The amounts of injected FITC-
conjugated pFN fragments were adjusted to equimolarheparin can block the accumulation of injected pFN-
FITC and specific cathepsin-induced FN fragments in amounts of molecules as compared to total pFN mole-
cules injected in previous experiments. As controls, NF1glomerulosclerotic lesions. These results provide evi-
dence for a domain-specific accumulation process in the hybrid mice were injected intravenously with either pFN
or one of the pFN fragments with or without pre-incuba-accumulation of circulating FN in sclerotic lesions.
tion with heparin.
METHODS Follow-up of F1 mice
Animals The urine albumin content of the GvHD F1 mice was
determined at two-week intervals, starting two weeksDBA/2 and C57BL/10*DBA/2 F1 hybrid mice were
purchased from Harlan BV (Horst, The Netherlands). before disease induction. Animals were kept in urine-
collection cages for 18 hours with free access to waterFemale DBA/2 mice aged 7 to 8 weeks served as donors
of lymphocytes in the induction of GvHD. Eight- to and food. The albumin levels were assessed by rocket
electrophoresis against rabbit anti-mouse albumin, with10-week-old female F1 hybrids served as recipients of
lymphocytes. GvHD was induced in 61 experimental F1 albumin as a standard (Sigma Chemical Corp., St. Louis,
MO, USA) [20].hybrid mice. Eleven age- and sex-matched normal F1
hybrid mice (NF1) were used as controls. The numbers Groups of three experimental mice were sacrificed at
weeks 0, 2, 4, 6, 8, 10, and 12 of GvHD. After perfusionof animals used for each experiment are detailed in the
results section. with PBS, the kidneys were removed. For light micro-
scopic examination with periodic acid-Schiff (PAS) re-
Induction of disease agent and phosphotungstic acid hematoxylin (PTAH), a
part of the kidney tissue was fixed in 10% buffered for-Graft versus host disease was induced in F1 hybrid
mice as described previously [20]. In brief, single cell malin, dehydrated, and then embedded in Paraplast
(Amstelstad, Amsterdam, The Netherlands). The re-suspensions were prepared from DBA/2 spleens, lymph
nodes, and thymi in Hank’s balanced salt solution (HBSS). maining tissue was frozen in CO2 ice-cooled isopentane
and stored at 70C until further use. Immunohisto-The total number of cells and the proportion of vital
cells were determined by Trypan blue staining. The sus- chemistry was performed with a fluorescein-isothiocya-
nate (FITC)-conjugated rat anti-mouse CD49e mono-pensions were mixed, and injected intravenously in F1
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clonal antibody (Pharmingen, San Diego, CA, USA) to 7.4. The digested pFN was allowed to bind to the column
by recirculation of the effluent, followed by the washingdetect the integrin 5 chain. The FITC-conjugated rabbit
anti-mouse CD49d monoclonal antibody (anti-integrin with three column volumes of equilibration buffer. The
pFN fragments were eluted by a discontinuous gradient4 chain) was a generous gift of Dr. E. Ruoslahti (Cancer
Research Center, La Jolla, CA, USA). Fluorescence in- subsequently consisting of 0.25 mol/L, 0.6 mol/L and 1
mol/L NaCl in equilibration buffer. The separate frac-tensity was scored semiquantitatively on a scale from 0 to
3, in which 0 represented no staining and 3 reflected a tions were analyzed by SDS-PAGE under reducing con-
ditions, dialyzed overnight against PBS/10 mmol/L EDTAvery strong staining. The slides were scored in a double-
blinded fashion by two observers independently of each at 4C, and labeled with FITC [21]. Fractions were
concentrated and washed by high-pressure diafiltrationother, using a Leitz fluorescence microscope. Represen-
tative examples of the scoring are shown in Figure 1. in a Centricon (Amicon), and stored at 20C until fur-
ther use.Eighteen hours after the injection of pFN or pFN
fragments, groups of mice were sacrificed. The numbers
Preparation of non-anticoagulant heparinof animals used for each experiment are detailed in the
Results section. After perfusion with phosphate-buf- Heparin (Organon Teknika Nederland BV, Boxtel,
The Netherlands) was converted into N-desulfated non-fered saline (PBS), the kidneys were removed and stored
for light and fluorescence microscopy as described above. anticoagulant heparin according to the procedure of In-
oue and Nagasawa [22]. In brief, sodium-heparin saltThe amount accumulation of pFN or pFN fragments was
scored semiquantitatively on a scale from 0 to 3, in dissolved in 0.1 mol/L HCl was converted into a pyridin-
heparin salt on a DOWEX column (Pharmacia, Uppsala,which 0 represented no accumulation and 3 reflected
a very strong accumulation. The slides were scored in a Sweden). Desulfation was performed by using dimethyl
sulfoxide/5% methanol. Activated partial thromboplas-double-blinded fashion by two observers independently
of each other, using a Leitz fluorescence microscope. tin time (aPTT) was performed according to the manu-
facturers protocol (Boehringer, Mannheim, Germany).Representative examples of the scoring are shown in
Figure 1. N-desulfated non-anticoagulant heparin had no effect on
the clotting time. In an enzyme-linked immunosorbent
pFN isolation and purification of pFN fragments assay (ELISA) under isotonic conditions, non-anticoag-
ulant heparin and anticoagulant heparin were found toPlasma fibronectin was isolated from normal mouse
plasma, in the presence of 30 mmol/L citrate as an antico- have comparable binding capacities to pFN (unpublished
results).agulant. The plasma was dialyzed overnight against
PBS/10 mmol/L EDTA at 4C. The plasma was spun
Statistical analysisdown at 3000  g for 20 minutes to remove protein
aggregates, after which the supernatant was circulated Results are presented as means SD where indicated,
and were analyzed using the Chi-square test. P 	 0.05over a gelatin-Sepharose 4B affinity column for two
hours. The column was rinsed with PBS/10 mmol/L was considered statistically significant.
EDTA. pFN was eluted from the column with 6 mol/L
urea in 0.1 mol/L citric acid/50 mmol/L Tris, pH 4.7. The
RESULTS
eluate was dialyzed overnight against PBS/10 mmol/L
Clinical course of GvHDEDTA at 4C before labeling with FITC [21]. For prepa-
ration of pFN fragments 10 mg of affinity-purified pFN Four weeks after the induction of GvHD, mice devel-
oped abnormal proteinuria. Albuminuria reached thewas dialyzed overnight against 50 mmol/L sodium acetate/
50 mmol/L NaCl/10 mmol/L EDTA, pH 6.4. The addi- highest levels at week 12 (results not shown). At this
time point the majority of the animals developed ascitestion of a 10% solution of glacial acetic acid was used to
adjust the pH of the dialysate to 3.5. Digestion with and edema. Light microscopy of kidney sections of
GvHD mice showed a lupus type of nephritis, compli-cathepsin D (Sigma-Aldrich N.V./S.A., Bornem, The
Netherlands) was performed for 18 hours at 37C in a cated by focal and segmental glomerulosclerosis starting
10 weeks after the induction of the disease (Fig. 1), con-weight ratio of FN:cathepsin D 
 200:1. Adjusting the
pH to 7 with 2.5 mol/L Tris (pH 9) terminated the reac- firming earlier results [20]. Furthermore, PTAH staining
showed fibrin deposited in sclerotic regions, suggestingtion. The digested pFN solution was tested by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS- that the coagulation pathway may be involved in the
development of glomerulosclerosis in GvHD (results notPAGE), under reducing conditions, before purification
of the fragments. shown).
Altered expression of integrins that specifically bindThe heparin-Sepharose 4B affinity column was equili-
brated with 20 mmol/L Tris/50 mmol/L NaCl/10 mmol/L to FN may well lead to enhanced binding of pFN in the
glomerulosclerotic lesions. Immunohistochemistry showedEDTA/5 mmol/L caproic acid/0.2 mmol/L PMSF, pH
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Fig. 1. Immunohistochemical staining of renal tissue. (A) Control staining with a non-immune IgG antibody. (B) Periodic acid-Schiff (PAS)
staining of a mouse glomerulus 10 weeks after the induction of graft versus host disease (GvHD), showing extensive glomerulosclerosis. (C) The
integrin 5 chain is expressed in minimal amounts in a glomerulus of a NF1 mouse. Increased expression of the integrin 5 chain is visible in the
periphery of the glomerulosclerotic lesion 8 weeks after the induction of GvHD (D). The integrin 4 chain was expressed in trace amounts in
glomeruli of NF1 mice (E). The expression of the integrin 4 chain did not alter during GvHD (F, GvHD week 10).
that both the integrin chains 4 and 5 were expressed GvHD. However, from week 6 on increased amounts of
the 5 integrin chain were observed in the periphery ofin minimal amounts in the glomeruli of NF1 mice (fluo-
rescence intensity /, diffuse pattern). The expression sclerotic lesions (segmental staining, fluorescence inten-
sity 3; Fig. 1). Control staining with an irrelevant non-of the integrin 4 did not alter during the development of
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FINC_mouse, 2477aa) shows more than 80% homology
with the human FN protein sequence (Swissprot: FINC_
human, 2386aa), the digestion of mouse FN with cathep-
sin D generated several different fragments (120, 60, and
100 kD) than digestion of human FN (70 kD gelatin
bindin domain, 27 kD N-terminal heparin binding do-
main, 40 kD collagen binding domain, 120 kD cell bind-
ing domain, and 55-65 kD C-terminal heparin binding
domain [23, 24]}. Results of N-terminal sequencing of
the fractions revealed that the protein-sequence of the
60 kD high-affinity fragment started at residue 1704Fig. 2. Polyacrylamide gel electrophoresis under reducing conditions
of plasma-fibronectin isolated from normal mouse plasma using a gela- (AQNRNGESQP). This fragment thus included the high-
tin-Sepharose 4B affinity column. Lane A represents molecular weight affinity heparin II binding domain. Repeated N-terminalmarkers. Lane B contains total fibronectin (FN) with an apparent molec-
sequencing of the low-affinity fraction suggested that theular weight (MW) of 220 kD. Lane C shows cathepsin D induced
fragments of total FN. There is no 220 kD FN band left after enzymatic N-terminus of the 120 kD fragment was located near the
digestion. Affinity purification of the fragment-mixture, on a heparin-
low-affinity heparin-binding domain, but we were notSepharose 4B column, resulted in a low-affinity fraction containing a
specific 120 kD FN fragment (lane D) and a high-affinity fraction con- able to find one unequivocal starting point for the se-
taining a specific 60 kD FN fragment (lane E). The low-affinity fraction quence. The 100 kD proteins in both samples were not(120 kD) was completely depleted of the 60 kD band, while the high-
affinity fraction (60 kD) did not contain any 120 kD FN fragments. identical to each other, but the 100 kD protein fragment
Additional pFN fragments with an apparent MW of about 100 kD are in the low-affinity fraction shared sequence homology
present in both fractions.
with the 120 kD pFN fragment, while the 60 kD pFN
fragment shared sequence homology with the 100 kD
protein fragment in the high-affinity fraction. Figure 3
immune IgG showed no fluorescence pattern in NF1 or shows a proposed schematic drawing of the FN protein
GvHD mice. sequence indicating the proposed locations of the FN
fragments.pFN isolation and purification of pFN fragments
Figure 2 shows the results of SDS-PAGE analysis of Both heparin and N-desulfated non-anti-coagulant
isolated pFN and pFN fragments under reducing condi- heparin prevent binding of pFN to
tions. Total pFN was isolated by affinity chromatography glomerulosclerotic lesions
and has a molecular weight of 220 kD (lane B). Incuba-
Fluorescein isothiocyanate (FITC)-conjugated pFN in-tion of pFN with cathepsin D for 18 hours led to complete
jected intravenously into mice 10 to 12 weeks after induc-digestion of pFN (lane C). Digestion for a longer period
tion of GvHD accumulated in the glomeruloscleroticof time or at a higher protein/proteinase ratio did not
lesions (N 
 9, fluorescence intensity 3; Fig. 4A). Theprovide any additional FN fragment bands. Incubation
for a shorter period showed incomplete digestion of FN, segmental fluorescent staining pattern was comparable
leaving remains of the 220 kD total FN band in the SDS- to the occurrence of PAS-positive glomerulosclerotic le-
PAGE gel (results not shown). Purification of the pFN sions. This accumulation was not observed in NF1 mice
fragments on a heparin affinity column revealed two (N 
 2), confirming earlier results by Bergijk et al [9].
separate fractions that could be eluted from the column Ex vivo pre-incubation of pFN-FITC with heparin re-
with 0.25 mol/L NaCl in an equilibration buffer (lane sulted in a significantly reduced accumulation of pFN-
D) and with 1 mol/L NaCl (lane E), respectively. No FITC upon injection (P 0.05). Hardly any fluorescence
fragments could be eluted with 0.6 mol/L NaCl. The signal was detectable in 4 out of 5 animals with GvHD
fraction with low affinity for heparin contained a specific (Fig. 4B, fluorescence intensity /). Injection of pFN
pFN fragment with an apparent molecular weight of 120
pre-incubated with non-anticoagulant, N-desulfated hepa-kD (lane D) and a mixture of additional bands with an
rin also prevented the accumulation of pFN-FITC in theapparent molecular weight around 100 kD. The fraction
glomerular lesions (P  0.05). Five GvHD mice showedwith high affinity for heparin contained a specific pFN
no accumulation, while only two animals had a weakfragment with an apparent molecular weight of 60 kD
fluorescent staining of 1. There was no statistically(lane E) and also a mixture of additional bands with
significant difference between the accumulation of pFN-an apparent molecular weight around 100 kD. No pFN
FITC pre-treated with heparin or non-anticoagulantprotein bands were visible in the gel below the 60 kD
heparin. Results of the accumulation experiments areband.
Although the mouse FN protein sequence (Swissprot: summarized in Table 1.
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Fig. 3. Schematic drawing of the total FN protein sequence (top) and the pFN protein sequence (bottom), with the proposed locations of the FN
fragments involved in the accumulation of FN in glomerulosclerotic lesions. Indicated are the EIIIA, EIIIB and V regions, which can be included
in or excluded from the protein by alternative splicing of the FN pre-mRNA. Rectangles represent homologous type I repeats, circles represent
homologous type II repeats, and squares represent homologous type III repeats. The protein sequence of the high-affinity fraction starts at residue
1704 (homology repeat III11), just before the high-affinity heparin-binding domain (Hep II). The N-terminus of the low-affinity fraction is suggested
to be located near the low-affinity heparin-binding domain (Hep I, homology repeat I1-5).
pFN binding in glomerulosclerotic lesions does not clearance, and wound healing. Several domains within
the FN molecule may be involved in the specific bindingoccur via the high-affinity binding site for heparin
to the sclerotic lesion. The actual accumulation of pFNIntravenous injection of the FITC-conjugated pFN
may result from (1) direct binding to other ECM compo-fraction with low affinity for heparin resulted in intense
nents in the damaged glomerulus, (2) direct binding tosegmental staining of glomeruli from 8 out of 11 mice
beta-1 integrins on cell surfaces, (3) involvement of thewith GvHD at week 10 (fluorescence intensity 2, Fig.
coagulation system, or (4) binding to itself by polymer-4C). This accumulation did not occur when the low-
ization via self-assembly sites into insoluble fibrils, oraffinity fraction was injected in NF1 mice (N 
 3). Ex
from a combination of these mechanisms.vivo incubation of the low-affinity pFN-FITC fraction
Firstly, FN can bind to other ECM molecules such aswith heparin inhibited its accumulation in the glomerulus
collagen and laminin that are produced and depositedof GvHD mice (N
 2). The FITC-conjugated pFN frac-
in the kidney to maintain a stable matrix. Alterations intion with high affinity for heparin did not accumulate in
the ECM turnover that may contribute to the accumula-the glomerulus of GvHD mice at week 10 (N 
 10, Fig.
tion of FN have been described to precede the develop-4D) nor of NF1 mice (N 
 3). There was no statistically
ment of glomerulosclerosis in the GvHD model [25].significant difference between the accumulation of the
Secondly, stabilization of the tissue also is obtained bylow-affinity fraction and the accumulation of total pFN-
the cell-to-cell and cell-to-substrate attachments via in-FITC, but there was a strong difference between the
tegrin receptors. FN has two major integrin binding sites.accumulation of total pFN-FITC and the accumulation
The first binding site is an RGD (Arg-Gly-Asp) sequenceof the high-affinity fraction (P  0.02)
in the central cell-binding domain that is recognized by
51 integrins. The second binding site, recognized by
DISCUSSION 41 integrins, is an LDV (Leu-Asp-Val) sequence lo-
cated in the alternatively spliced V-region. This studyCirculating pFN, which is produced by the liver, accu-
mulates in glomerulosclerotic lesions at a late stage in shows an increase in the expression of the 5 integrin
chain in areas surrounding the glomerulosclerotic lesionsGvHD [9]. This dimeric glycoprotein is known to play
a role in a variety of cellular processes, immune complex (Fig. 1). This altered integrin expression in the glomeru-
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Fig. 4. Immunofluorescence micrographs of mouse glomeruli 10 weeks after the induction of GvHD, and 18 hours after injection with pFN-FITC
(A), pFN-FITC pre-incubated with heparin (B), low-affinity pFN-FITC fraction (C), or high-affinity pFN-FITC fraction (D). Injection of the low-
affinity pFN fraction pre-incubated with heparin shows a significantly reduced pattern of accumulation, comparable to the pattern shown in panel B.
lus during the course of the disease may lead to enhanced minished the development of fibronectin-containing end-
stage sclerotic lesions in 50 to 80% of the animals at weekbinding of pFN.
A third mechanism that may participate in the accu- 11 of the disease. This points toward the involvement of
the coagulation cascade in the process of FN accumula-mulation of pFN in the glomerulus is activation of the
coagulation system. PTAH staining showed deposition tion leading to the development of end-stage sclerotic
lesions. However, to our surprise, treatment of mice withof fibrin in the glomerulosclerotic lesions during the
development of GvHD, indicating an activation of the N-desulfated non-anticoagulant heparin showed a simi-
lar effect. This indicates that the protective effect ofcoagulation cascade during the induction of the dis-
ease. Therapeutical intervention in the coagulation cas- heparin in the trapping of FN in the glomerulosclerotic
lesions is independent of the anti-coagulant propertiescade can be achieved by treating the mice with heparin.
We earlier performed an experiment that investigated of heparin. We then hypothesized that heparin treatment
directly interferes with FN accumulation by binding towhether heparin treatment in a late stage of GvHD could
significantly affect the development of glomerulosclero- FN, that is, without participation of the coagulation
system.sis in vivo (abstract; Bergijk et al, J Am Soc Nephrol
6:892, 1995). Seven weeks after induction of GvHD the Fibronectin has been shown to contain two heparin-
binding sites. The high-affinity heparin II binding domainglomeruli showed mesangial matrix expansion and thick-
ening of the GBM. From this moment on, mice (N 
 located at the carboxyterminal site of FN (III12-14) has a
dual function. The heparin II binding domain is thought5/group) were treated with different doses of heparin
(20 or 40 U/24 h). High dose treatment significantly di- to interact with cell surface glycosaminoglycans to facili-
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Table 1. Summary of fibronectin (FN) accumulation experiments treatment could result from steric hindrance of the spe-
10–12 weeks after induction of graft-vs.-host disease (GvHD)
cific binding site, or heparin might act via other unknown
Pre-incubation with mechanisms. Therefore, we conclude that: (a) the protec-
Administration of Buffer Heparin N-desulfated heparin tive effect of heparin is independent of its anticoagulant
properties, suggesting that the coagulation cascade is notTotal pFN  / /
(N 
 9) (N 
 5) (N 
 5) involved in the trapping of FN in the sclerotic lesion;
High-affinity (b) the process of glomerulosclerosis is not mediated via
pFN fraction 0 0
the heparin II binding site of FN; and (c) the site involved(N 
 10) (N 
 2) ND
Low-affinity in the accumulation of FN in the glomerulus is located
pFN fraction  0 on or near the heparin I binding site.
(N 
 11) (N 
 2) ND
A final remark concerns the possible functional in-
Results are scored semiquantitatively on a scale from 0 to , in which 0
volvement of the heparin I binding site in the glomerularrepresents no accumulation of FITC-conjugated plasma fibronectin (pFN) or
pFN fragments, and  reflects very strong accumulation in the glomerulo- accumulation and stabilization of FN in the diseased
sclerotic lesions, as determined by direct immunofluorescence. Abbreviations
glomeruli. As mentioned above, it is known that theare: ND, not determined; N, number of animals
heparin I binding domain contains a self-assembly site
which is instrumental in polymerization of FN into insol-
uble FN fibrils [29, 30]. Self-assembly of FN dimers into
tate cell adhesion and spreading [26, 27], but it also plays insoluble fibrils is thought to involve primarily interac-
an important role in matrix assembly [28], probably via tions between the first five type I (I1-5) repeats located
interactions with I1-5. In addition to the high-affinity hepa- on the low-affinity heparin I binding domain, and the
rin II binding domain, FN also has a low-affinity binding first type III (III1) repeat located nearby [31–34]. Treat-
domain for heparin (heparin I binding domain) located ment of purified FN in solution with an III1-C fragment
on I1-5. The heparin I domain is also involved in matrix resulted in the appearance of FN multimers, called super-
assembly and, in particular, FN self-assembly [29, 30]. fibronectin, which resemble matrix fibrils [35]. It has
To test the possible involvement of either of the hepa- been suggested that this self-assembly site of FN is pro-
rin-binding sites of FN in its glomerular accumulation, tected from spontaneous polymerization by keeping it
we performed an experiment in which GvHD mice were cryptic, and that it is only unmasked in response to either
injected with pFN-FITC pre-incubated with heparin or physiological stimuli, or to tissue repair reactions. Based
N-desulfated heparin. Our results show that pre-incuba- on these observations and ours, we hypothesize that self-
tion with heparin prevents FN accumulation in the scle- assembly of soluble pFN after binding to FN molecules
rotic lesions. Similar results were obtained using N-desul- already present in the glomerular ECM contributes to
fated non-anticoagulant heparin (Table 1). This suggests the observed accumulation of FN during the develop-
the involvement of either one of the heparin binding ment of glomerulosclerosis in a late stage of GvHD.
sites of FN in its glomerular accumulation. To investigate In conclusion, our results provide evidence for pro-
whether FN binds to the glomerulus via its high- or low- gressive accumulation of FN in glomerulosclerotic le-
affinity heparin-binding domain, FN was digested with sions in our model via its low-affinity heparin-binding
cathepsin D, after which the fragments were separated site or a site nearby. This may involve a self-assembly
on a heparin affinity column. Thus, two batches of FN process involving the first five type I (I1-5) repeats, or the
fragments were obtained with either low or high affinity first type III (III1) repeat, or both. However, the extent
to which this self-assembly initial binding of FN to eitherfor heparin, respectively. The 100 kD fragments present
ECM or beta 1 integrins precedes process requires fur-in both fractions appeared to have no functional effect
ther investigation.during the accumulation experiments. Further molecular
dissection of these fragments will be required to obtain
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